These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37371584)

  • 41. Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.
    Ku E; Campese VM
    Pediatr Nephrol; 2009 Dec; 24(12):2301-7. PubMed ID: 19347366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
    Wilkinson-Berka JL; Tan G; Jaworski K; Harbig J; Miller AG
    Circ Res; 2009 Jan; 104(1):124-33. PubMed ID: 19038868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.
    Lyubarova R; Gosmanova EO
    Curr Hypertens Rep; 2017 May; 19(5):40. PubMed ID: 28451852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vascular and inflammatory mineralocorticoid receptors in kidney disease.
    Barrera-Chimal J; Jaisser F
    Acta Physiol (Oxf); 2020 Feb; 228(2):e13390. PubMed ID: 31529757
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mineralocorticoid Receptor Activation in Vascular Insulin Resistance and Dysfunction.
    Igbekele AE; Jia G; Hill MA; Sowers JR; Jia G
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012219
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aldosterone in heart failure: pathophysiology and treatment.
    Struthers AD
    Curr Heart Fail Rep; 2004 Dec; 1(4):171-5. PubMed ID: 16036041
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation.
    Gros R; Ding Q; Liu B; Chorazyczewski J; Feldman RD
    Am J Physiol Cell Physiol; 2013 Mar; 304(6):C532-40. PubMed ID: 23283935
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aldosterone in the pathogenesis of chronic kidney disease and proteinuria.
    Lu Y; Ku E; Campese VM
    Curr Hypertens Rep; 2010 Aug; 12(4):303-6. PubMed ID: 20596805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
    Schäfer N; Lohmann C; Winnik S; van Tits LJ; Miranda MX; Vergopoulos A; Ruschitzka F; Nussberger J; Berger S; Lüscher TF; Verrey F; Matter CM
    Eur Heart J; 2013 Dec; 34(45):3515-24. PubMed ID: 23594590
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aldosterone induces fibrosis, oxidative stress and DNA damage in livers of male rats independent of blood pressure changes.
    Queisser N; Happ K; Link S; Jahn D; Zimnol A; Geier A; Schupp N
    Toxicol Appl Pharmacol; 2014 Nov; 280(3):399-407. PubMed ID: 25204689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aldosterone synthase knockout mouse as a model for sodium-induced endothelial sodium channel up-regulation in vascular endothelium.
    Jeggle P; Hofschröer V; Maase M; Bertog M; Kusche-Vihrog K
    FASEB J; 2016 Jan; 30(1):45-53. PubMed ID: 26324851
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aldosterone as a determinant of cardiovascular and renal dysfunction.
    Epstein M
    J R Soc Med; 2001 Aug; 94(8):378-83. PubMed ID: 11461980
    [No Abstract]   [Full Text] [Related]  

  • 56. Aldosterone remodels human endothelium.
    Oberleithner H; Riethmüller C; Ludwig T; Hausberg M; Schillers H
    Acta Physiol (Oxf); 2006; 187(1-2):305-12. PubMed ID: 16734767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human endothelium: target for aldosterone.
    Oberleithner H; Ludwig T; Riethmüller C; Hillebrand U; Albermann L; Schäfer C; Shahin V; Schillers H
    Hypertension; 2004 May; 43(5):952-6. PubMed ID: 14993200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aldosterone: effects on the kidney and cardiovascular system.
    Briet M; Schiffrin EL
    Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
    Epstein M
    Am J Med; 2006 Nov; 119(11):912-9. PubMed ID: 17071154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
    Maron BA; Zhang YY; White K; Chan SY; Handy DE; Mahoney CE; Loscalzo J; Leopold JA
    Circulation; 2012 Aug; 126(8):963-74. PubMed ID: 22787113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.